Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People’s Republic of China

Neuropsychiatric Disease and Treatment

Volumn 12, Issue , 2016, Pages 941-949

  Zhang, Ling ^a,b,c,d   Chen, Yun ^e   Yue, Li ^e   Liu, Qingjing ^f   Montgomery, William ^g   Zhi, Lihua ^e   Wang, Wanqi ^e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NATIONAL CLINICAL RESEARCH CENTER FOR GERIATRIC DISORDERS   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Shanghai Engineering Research   (China)

^f State Key Laboratory of Space Ground Integrated Information Technology   (China)

^g ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Antidepressants; Depression; Health care resource; People s Republic of China; Persistence

Indexed keywords

ANTIDEPRESSANT AGENT; MAPROTILINE; MIANSERIN; NEFAZODONE; NEUROSTAN; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; PROPION; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRAZODONE; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; CHINA; COMORBIDITY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; OUTPATIENT CARE; RETROSPECTIVE STUDY; TREATMENT DURATION; URBAN POPULATION;

EID: 84964411837     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S97407     Document Type: Article

References (36)

1. Brown CH. Pharmacotherapy of major depressive disorder. US Pharm. 2011;36(11):HS3–HS8.
2. Jiang K. Prevention and Treatment Guideline of Depression Disorder. 1st ed. Beijing: Peking University Medical Press; 2007. [Chinese].
3. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res. 2003;12(1):3–21.
4. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication (NCS-R). Arch Gen Psychiatry. 2005;62:617–627.
5. Ma X, Li S, Xiang Y. An epidemiological survey on depressive disorder in Beijing area. Chin J Psychiatry. 2007;40(2):100–103.
6. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association (APA); 2010.
7. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics. 2000;18(2):143–148.
8. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.
9. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9(2):87–98.
10. Global Burden of Disease Analysis 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Analysis 2013. Lancet. 2015;386(9995):743–800.
11. Zhou X, Chen X. [Researches on depression economic burden]. Shanghai Med Pharm J. 2006;27(12):539–541. [Chinese].
12. Zhai J, Zhao J, Chen M, Su Z. An investigation on economic costs of major depression in Shandong. Chin J Nerv Ment Dis. 2008;34(3):165–168.
13. Zhai J, Chen M, Zhao J, Yang H, Zhang Q, Wang K. An investigation on family burden of depressive disorder in Shandong province of China. J Int Psychiatry. 2012;39(1):5–9.
14. Cui Z, Faries D, Gelwicks S, Novick D, Liu X. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ. 2012;15(1):1–15.
15. Warden D, Rush AJ, Wisniewski SR, et al. What predicts attrition in second step medication treatments for depression?: a STAR*D report. Int J Neuropsychopharmacol. 2009;12(4):459–473.
16. WHO Collaborating Center for Drug Statistics Methodology [homepage on the Internet]. Definition and General Considerations. Available from: http://www.whocc.no/ddd/definition_and_general_considera/. Accessed February 1, 2016.
17. Wikipedia [homepage on the Internet]. List of World Bank Nominal Exchange Rates. Available from: https://en.wikipedia.org/wiki/List_of_renminbi_exchange_rates. Accessed February 1, 2016.
18. Shan H [homepage on the Internet]. [Main Direction of Mental Health Work in Contemporary China]. Available from: http://www.myeducs.cn/mianfeilunwen/dangdaizhongguo/10110597/. Accessed February 1, 2016. [Chinese].
19. Harvey CA, Fielding JM. The configuration of mental health services to facilitate care for people with schizophrenia. Med J Aust. 2003;178(9):49–52.
20. Lipsitt DR. Psychiatry and the general hospital in an age of uncertainty. World Psychiatry. 2003;2(2):87–92.
21. Cui B, Du C, Wang Y, et al. [Analysis on antidepressants used in Tianjin medical institutions in 2006]. Tianjin Pharm. 2009;21(2):26–28. [Chinese].
22. Soh TH, Lim L, Chan HN, Chan YH. Antidepressant prescribing patterns for depressive and anxiety disorders in a Singapore hospital. Open J Psychiatry. 2015;5:144–152.
23. Ministry of Health. Patterns of Antidepressant Drug Prescribing and Intentional Self-Harm Outcomes in New Zealand: An Ecological Analysis. Wellington: Ministry of Health; 2007.
24. Lee P, Zhang M, Hong JP, et al. Frequency of painful physical symptoms with major depressive disorder in Asia: relationship with disease severity and quality of life. J Clin Psychiatry. 2009;70(1):83–91.
25. Novick D, Montgomery WS, Aguado J, Peng X, Brugnoli R, Haro JM. Which somatic symptoms are associated with an unfavorable course in Chinese patients with major depressive disorder? Asia Pac Psychiatry. 2015;7(4):427–435.
26. Emyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30–33.
27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–2107.
28. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661.
29. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300–303.
30. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96–106.
31. Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv. 2001;52(12):1615–1620.
32. Shi S, Lu Z, Zhu S, et al. Seeking behavior of patients with mental disorders and interfering factors. Natl Med J China. 2000;80(1):75–78.
33. Bao LJ, Hu ZH, Han DL, Jiang BS, Ying HF. Predictors of antidepressant adherence of discharged patients with major depressive disorder. J Neurosci Ment Health. 2014;14(5):469–473.
34. Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv. 2009;60(5):617–623.
35. Soh TH, Lim L, Chan HN, Chan YH. Antidepressant prescribing patterns for depressive and anxiety disorders in a Singapore hospital. Open Journal of Psychiatry. 2015;5:144–152.
36. The Central People’s Government of the People’s Republic of China [homepage on the Internet]. [Beijing Gross Regional Product Growth 7.7% and GDP Per Capital 87, 091 Yuan in 2012]. Available from: http://www.gov.cn/gzdt/2013-01/21/content_2316558.htm. Accessed February 1, 2016. [Chinese].